Log in

NASDAQ:MNKDMannKind Stock Price, Forecast & News

+0.01 (+0.63 %)
(As of 08/12/2020 04:00 PM ET)
Today's Range
Now: $1.60
50-Day Range
MA: $1.70
52-Week Range
Now: $1.60
Volume1.94 million shs
Average Volume3.06 million shs
Market Capitalization$366.68 million
P/E RatioN/A
Dividend YieldN/A
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Read More
MannKind logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.87 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MNKD



Sales & Book Value

Annual Sales$63.04 million
Book Value($0.92) per share


Net Income$-51,900,000.00


Market Cap$366.68 million
Next Earnings Date11/4/2020 (Estimated)
+0.01 (+0.63 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

MannKind (NASDAQ:MNKD) Frequently Asked Questions

How has MannKind's stock price been impacted by COVID-19?

MannKind's stock was trading at $1.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 45.5% and is now trading at $1.60.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of MannKind?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for MannKind

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for MannKind

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.00. The biopharmaceutical company earned $15.11 million during the quarter, compared to analyst estimates of $15.19 million.
View MannKind's earnings history

What price target have analysts set for MNKD?

5 equities research analysts have issued 12-month price targets for MannKind's stock. Their forecasts range from $2.50 to $4.00. On average, they anticipate MannKind's stock price to reach $3.00 in the next year. This suggests a possible upside of 87.5% from the stock's current price.
View analysts' price targets for MannKind

Has MannKind been receiving favorable news coverage?

News headlines about MNKD stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MannKind earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about MannKind

Who are some of MannKind's key competitors?

What other stocks do shareholders of MannKind own?

Who are MannKind's key executives?

MannKind's management team includes the following people:
  • Dr. Michael E. Castagna, CEO & Director (Age 42)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 56)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 55)
  • Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 58)
  • Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 52)

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (0.83%), Emerald Mutual Fund Advisers Trust (0.75%), Bank of New York Mellon Corp (0.29%), Dupont Capital Management Corp (0.31%), 180 Wealth Advisors LLC (0.22%) and California Public Employees Retirement System (0.21%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind

Which major investors are buying MannKind stock?

MNKD stock was purchased by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, California Public Employees Retirement System, Bank of New York Mellon Corp, New York State Common Retirement Fund, SG Americas Securities LLC, 180 Wealth Advisors LLC, and Beirne Wealth Consulting Services LLC. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $1.60.

How big of a company is MannKind?

MannKind has a market capitalization of $366.68 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 225 workers across the globe.

What is MannKind's official website?

The official website for MannKind is www.mannkindcorp.com.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.